BridgeBio Pharma, Inc. (MUN:2CL)
Germany
· Delayed Price · Currency is EUR 62.18
+7.98 (14.72%)
At close: Dec 1, 2025
BridgeBio Pharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Net Income | -724.93 | -535.76 | -643.2 | -481.18 | -562.54 | Upgrade
|
| Depreciation & Amortization | 5.43 | 6.08 | 6.49 | 6.77 | 5.84 | Upgrade
|
| Other Amortization | 5.97 | 7.46 | 8.91 | - | - | Upgrade
|
| Loss (Gain) From Sale of Assets | - | -178.32 | 1.24 | 6.26 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | 12.72 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | -8.14 | -18.31 | 8.22 | -29.91 | Upgrade
|
| Loss (Gain) on Equity Investments | 63.78 | 31.18 | - | - | - | Upgrade
|
| Stock-Based Compensation | 133.02 | 95.8 | 108.71 | 91.56 | 99.51 | Upgrade
|
| Other Operating Activities | 121.89 | 28.93 | 3.39 | -91.92 | -6.43 | Upgrade
|
| Change in Accounts Receivable | -134.72 | -2.97 | 15.33 | 15.17 | -19.75 | Upgrade
|
| Change in Inventory | -25.31 | - | - | - | - | Upgrade
|
| Change in Accounts Payable | 26.61 | 1.51 | 2.78 | -0.35 | 2.83 | Upgrade
|
| Change in Unearned Revenue | -11.43 | 21.88 | -5.44 | 15.26 | - | Upgrade
|
| Change in Other Net Operating Assets | 93.78 | 11.63 | -7.61 | -2 | 12.52 | Upgrade
|
| Operating Cash Flow | -445.91 | -520.73 | -527.72 | -419.49 | -497.93 | Upgrade
|
| Capital Expenditures | -1.1 | -0.93 | -1.31 | -4.82 | -13.25 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | 10 | - | Upgrade
|
| Cash Acquisitions | - | - | - | - | 13.65 | Upgrade
|
| Divestitures | - | -0.14 | -0.5 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -8.5 | -7.98 | - | -1.5 | -35 | Upgrade
|
| Investment in Securities | -17.2 | 44.15 | 55.84 | 339.47 | -166.23 | Upgrade
|
| Other Investing Activities | 2.3 | 25.68 | - | 110 | - | Upgrade
|
| Investing Cash Flow | -24.49 | 60.78 | 54.03 | 453.15 | -200.83 | Upgrade
|
| Long-Term Debt Issued | 875 | 950 | - | - | 1,204 | Upgrade
|
| Long-Term Debt Repaid | -459 | -473.42 | - | -20.49 | -124.12 | Upgrade
|
| Net Debt Issued (Repaid) | 416 | 476.58 | - | -20.49 | 1,080 | Upgrade
|
| Issuance of Common Stock | 34.15 | 322.9 | 459.22 | 8.08 | 20.46 | Upgrade
|
| Repurchase of Common Stock | -62.5 | -7.53 | -6.88 | -1.56 | -204.75 | Upgrade
|
| Other Financing Activities | -28.35 | -43.5 | -0.8 | 0.84 | -158.95 | Upgrade
|
| Financing Cash Flow | 359.29 | 748.46 | 451.54 | -13.13 | 736.45 | Upgrade
|
| Net Cash Flow | -111.1 | 288.51 | -22.15 | 20.52 | 37.69 | Upgrade
|
| Free Cash Flow | -447.01 | -521.66 | -529.03 | -424.32 | -511.18 | Upgrade
|
| Free Cash Flow Margin | -89.03% | -235.08% | -5686.62% | -546.46% | -733.23% | Upgrade
|
| Free Cash Flow Per Share | -2.33 | -2.80 | -3.25 | -2.88 | -3.54 | Upgrade
|
| Cash Interest Paid | 43.67 | 91.34 | 61.11 | 54.44 | 29.77 | Upgrade
|
| Cash Income Tax Paid | 1.2 | - | - | - | - | Upgrade
|
| Levered Free Cash Flow | -325.29 | -291.12 | -240.16 | -285.88 | -301.13 | Upgrade
|
| Unlevered Free Cash Flow | -219.86 | -236.53 | -198.26 | -235.61 | -271.89 | Upgrade
|
| Change in Working Capital | -51.06 | 32.04 | 5.06 | 28.08 | -4.4 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.